<DOC>
	<DOCNO>NCT00685399</DOCNO>
	<brief_summary>This study test efficacy safety AIN457 patient active uveitis require systemic immunosuppression .</brief_summary>
	<brief_title>Safety Efficacy AIN457 Noninfectious Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Inclusion criterion : Active uveitis ( i.e. , uveitis remission ) . Intermediate uveitis , posterior uveitis , panuveitis must sufficiently severe systemic immunosuppression indicate . Exclusion criterion : Active infection . Weight must great 120kg . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Uveitis ,</keyword>
	<keyword>eye ,</keyword>
	<keyword>IL-17 ,</keyword>
	<keyword>IL-17A ,</keyword>
	<keyword>IL17 ,</keyword>
	<keyword>AIN457 ,</keyword>
	<keyword>Vogt-Koyanagi-Harada ,</keyword>
	<keyword>Behcet 's ,</keyword>
	<keyword>Behcet ,</keyword>
	<keyword>Sympathetic ophthalmia ,</keyword>
	<keyword>Multifocal choroiditis ,</keyword>
	<keyword>Birdshot ,</keyword>
	<keyword>HLA-B27 ,</keyword>
	<keyword>Birdshot retinochoroiditis ,</keyword>
	<keyword>Retinal vasculitis ,</keyword>
	<keyword>Sarcoidosis ,</keyword>
	<keyword>Intermediate uveitis ,</keyword>
	<keyword>Panuveitis ,</keyword>
	<keyword>Posterior uveitis</keyword>
</DOC>